EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma

Tianqi Luo, Zhijin Fan, Anyu Zeng, Anqi Wang, Yuanwei Pan, Yanyang Xu, Hongmin Chen, Weiqing Chen, Dingmeng Nie, Jiaming Lin, Anfei Huang, Ming Gong und 5 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202410427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Tianqi Luo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Su…. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms, Drug Delivery Systems, Biomimetics. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Cancer Innovative Research Program of Sun Yat-sen University Cancer Center, Postdoctoral Fellowship Program of China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The high heterogeneity and severe side effects of chemotherapy are major factors contributing to the failure of osteosarcoma treatment. Herein, a comprehensive genomic analysis is conducted, and identified two prominent characteristics of osteosarcoma: significant cyclin‐dependent kinases 4 (CDK4) amplification and homologous recombination repair deficiency. Based on these findings, a co‐delivery system loaded with CDK4/6 inhibitors and poly ADP‐ribose polymerase (PARP) inhibitors is designed. By employing metal–organic frameworks (MOFs) as carriers, issue of drug insolubility is effectively addressed, while also enabling controlled release in response to the tumor microenvironment. To enhance targeting capability and biocompatibility, the MOFs are further coated with a bio‐membrane targeting B7H3. This targeted biomimetic co‐delivery system possesses several key features: 1) it can precisely target osteosarcoma with high B7H3 expression; 2) the combination of CDK4/6 inhibitors and PARP inhibitors exhibits synergistic effects, significantly impairing tumor's DNA repair capacity; and 3) the system has the potential for combination with photodynamic therapy, amplifying DNA repair defects to maximize tumor cell eradication. Furthermore, it is observed that this co‐delivery system can activate immune microenvironment, increasing CD8 + T cell infiltration and converting osteosarcoma from an immune‐cold to an immune‐hot tumor. In summary, the co‐delivery system is an effective therapeutic strategy and holds promise as a novel approach for osteosarcoma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaBone NeoplasmsDrug Delivery SystemsBiomimeticsHumansAnimalsCell Line, TumorPoly(ADP-ribose) Polymerase InhibitorsMicePrecision MedicineTumor MicroenvironmentCyclin-Dependent Kinase 4Metal-Organic Frameworks

Stichwörter der Autor:innen

B7H3Homologous recombination repairbioinformaticsnanoparticlesosteosarcoma

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsCyclin-Dependent Kinase 4Metal-Organic Frameworks

Autor:innen und Institutionen

  • Department of Musculoskeletal Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
  • Institute for Engineering Medicine, Kunming Medical University, Kunming, 650500, China.
  • Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, 518132, China.
  • Department of Joint Surgery, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510060, China.
  • Department of Pediatric Orthopaedics, Guangzhou Women and Children's Medical Center, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou Medical University, Guangzhou, 510630, China.
  • Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.

ORCID-Profile: Lang Rao

Förderung

  • National Natural Science Foundation of China
  • Cancer Innovative Research Program of Sun Yat-sen University Cancer Center
  • Postdoctoral Fellowship Program of China Postdoctoral Science Foundation
  • The Chinese Anti-Cancer Association - Hengrui PARP Inhibitor Oncology Research Fund

Zitieren

APA

Luo, T., Fan, Z., Zeng, A., Wang, A., Pan, Y., Xu, Y., Chen, H., Chen, W., Nie, D., Lin, J., Huang, A., Gong, M., Huang, Y., Ding, Y., Zhu, X., Rao, L., & Wang, J. (2025). Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma. Advanced Science. https://doi.org/10.1002/advs.202410427

Vancouver

Luo T, Fan Z, Zeng A, Wang A, Pan Y, Xu Y, et al. Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma. Advanced Science. 2025. doi:10.1002/advs.202410427

BibTeX
@article{Luo2025,
  author = {Luo, Tianqi and Fan, Zhijin and Zeng, Anyu and Wang, Anqi and Pan, Yuanwei and Xu, Yanyang and Chen, Hongmin and Chen, Weiqing and Nie, Dingmeng and Lin, Jiaming and Huang, Anfei and Gong, Ming and Huang, Yufeng and Ding, Yun and Zhu, Xiaojun and Rao, Lang and Wang, Jin},
  title = {Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202410427}
}
Kostenlos starten →